Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Wave Life Sci Ord Sh (NQ: WVE ) 14.20 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Wave Life Sci Ord Sh < Previous 1 2 3 Next > Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024 November 04, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs October 30, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Rockets 70% on Historic RNA Editing Success October 18, 2024 Wave Life Sciences' RNA editing advances have generated investor interest as the company strives to become a leading force in the treatment of genetic diseases. Via MarketBeat Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency October 16, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024 October 16, 2024 Event will highlight WVE-006 for AATD and Wave’s rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE... From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares October 01, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference September 30, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants September 25, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants September 24, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping September 24, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut September 20, 2024 Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment. Via MarketBeat Topics Economy Exposures Interest Rates Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy August 12, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024 August 01, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease June 25, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing June 12, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference May 30, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer May 09, 2024 Appointment builds on Wave’s recent progress advancing innovative genetic targets, such as INHBE, and continues to add significant experience to accelerate the rapid identification and translation of... From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference May 07, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024 May 02, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD) April 30, 2024 Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing April 23, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at Upcoming Investor Conferences March 27, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 06, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024 February 28, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy February 27, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Sarepta Therapeutics Inc.: Why it's a rising gene therapy star January 23, 2024 Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. Via MarketBeat Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones January 08, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
